AC Immune SA (NASDAQ:ACIU) Short Interest Update

AC Immune SA (NASDAQ:ACIU) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 509,400 shares, a decline of 9.1% from the March 31st total of 560,600 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 180,700 shares, the days-to-cover ratio is presently 2.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of AC Immune in a report on Friday, March 15th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of AC Immune during the fourth quarter valued at about $48,000. Nixon Peabody Trust Co. acquired a new stake in AC Immune in the 4th quarter valued at $64,000. Platinum Investment Management Ltd. increased its stake in AC Immune by 14.6% during the 4th quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock valued at $7,578,000 after purchasing an additional 193,123 shares in the last quarter. Avidity Partners Management LP boosted its stake in AC Immune by 2.3% during the 3rd quarter. Avidity Partners Management LP now owns 2,969,800 shares of the company’s stock valued at $8,464,000 after purchasing an additional 66,522 shares during the last quarter. Finally, BVF Inc. IL raised its position in AC Immune by 96.2% in the fourth quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock worth $72,856,000 after acquiring an additional 7,142,857 shares during the period. 51.36% of the stock is currently owned by institutional investors.

AC Immune Trading Up 2.6 %

ACIU stock opened at $2.35 on Monday. The stock has a 50-day moving average price of $3.09 and a two-hundred day moving average price of $3.34. The stock has a market cap of $232.42 million, a PE ratio of -3.31 and a beta of 1.00. AC Immune has a 1 year low of $1.78 and a 1 year high of $5.14.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $16.71 million for the quarter, compared to analyst estimates of $16.36 million. On average, analysts forecast that AC Immune will post -0.78 earnings per share for the current fiscal year.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.